Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis

Centre Hospitalier Universitaire de Nice

Status: Completed

Conditions: Atopic Dermatitis; Psoriasis

Treatments: Other: 3 Biopsies; Other: 2 biopsies; Other: biopsy

Study type: Interventional

Funder types: Other

Identifiers

NCT01538342

11-API-03

Details and patient eligibility

About

Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated. Transgenic mice expressing the cleaved form of caspases by Lyn, a tyrosine kinase Src family, develop an inflammatory syndrome with the characteristics of human psoriasis.

To clarify the relationship between the cleaved form of Lyn by caspases and psoriasis, the investigators intend to develop a clinical study to analyze the expression, cleavage and activity of Lyn and the activation of caspases from skin biopsies of patients with this disease.

This study will be conducted on a cohort of patients with different forms of psoriasis (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated with chronic inflammation. Thus, the investigators will evaluate the expression and activity of Lyn from skin lesion (L) and non-lesional (NL) from the same patient in parallel with the level of caspase activation and apoptotic inflammatory.

Thus, the investigators will verify that the cleavage by caspases of Lyn is associated specifically with psoriasis, as the investigators believe, or more generally to the skin inflammation. The investigators work would then define the cleavage by caspases of Lyn as a new potential marker of human psoriasis.

Enrollment: 170 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Psoriasis arms:

• Plaque psoriasis and erythrodermic more than 10% of body surface area.

• Pustular psoriasis of at least 1% of body surface.

  • Atopic dermatitis arm:Patients with atopic dermatitis has been identified and inflammatory lesions on the skin.
  • Healthy arm:People not suffering from any skin disease

Exclusion criteria

• Systemic treatment of psoriasis for at least 4 weeks and / or local treatment for at least 2 weeks at the time of study entry.
• Patient with significant infection and / or immunocompromised.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

170 participants in 5 patient groups

chronic plaque psoriasis

Other group

Description:

3 biopsies: 2 lesional and 1 non-lesional

Treatment:

Other: 3 Biopsies

pustular psoriasis

Other group

Description:

3 biopsies: 2 lesional and 1 non-lesional

Treatment:

Other: 3 Biopsies

erythrodermic psoriasis

Other group

Description:

3 biopsies: 2 lesional and 1 non-lesional

Treatment:

Other: 3 Biopsies

atopic dermatitis

Other group

Description:

2 biopsies: 1 lesional and 1 non-lesional

Treatment:

Other: 2 biopsies

healthy patients

Other group

Description:

1 biopsy of healthy skin.

Treatment:

Other: biopsy